Oruka Therapeutics (ORKA) Operating Leases (2020 - 2026)

Oruka Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Operating Leases rose 69.73% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 69.73% YoY), while the FY2025 annual figure was $1.3 million, up 73.91% from the prior year.
• Operating Leases was $1.1 million for Q1 2026 at Oruka Therapeutics, down from $1.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.7 million in Q2 2025 to a low of $24000.0 in Q2 2024.
• Historically, Operating Leases has averaged $616470.6 across 5 years, with a median of $435000.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Operating Leases tumbled 92.71% in 2024, then surged 6841.67% in 2025.
• A 5-year view of Operating Leases shows it stood at $280000.0 in 2022, then fell by 27.14% to $204000.0 in 2023, then soared by 270.1% to $755000.0 in 2024, then soared by 73.91% to $1.3 million in 2025, then decreased by 14.17% to $1.1 million in 2026.
• The last three Operating Leases figures came in at $1.1 million (Q1 2026), $1.3 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.